74 related articles for article (PubMed ID: 23069926)
21. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: the Canadian perspective.
Mernagh P; Suebwongpat A; Silverberg J; Weston A
Value Health; 2010; 13(2):180-7. PubMed ID: 19818064
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy.
Molinaro E; Viola D; Passannanti P; Agate L; Lippi F; Ceccarelli C; Pinchera A; Elisei R
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):490-502. PubMed ID: 19910902
[TBL] [Abstract][Full Text] [Related]
24. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
25. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
Schlumberger M; Ricard M; De Pouvourville G; Pacini F
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii.
Rotman-Pikielny P; Reynolds JC; Barker WC; Yen PM; Skarulis MC; Sarlis NJ
J Clin Endocrinol Metab; 2000 Jan; 85(1):237-44. PubMed ID: 10634393
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human thyrotropin in the management of thyroid cancer.
McDougall IR; Weigel RJ
Curr Opin Oncol; 2001 Jan; 13(1):39-43. PubMed ID: 11148684
[TBL] [Abstract][Full Text] [Related]
29. Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.
Krausz Y; Uziely B; Nesher R; Chisin R; Glaser B
Isr Med Assoc J; 2001 Nov; 3(11):843-9. PubMed ID: 11729583
[TBL] [Abstract][Full Text] [Related]
30. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective.
Mernagh P; Campbell S; Dietlein M; Luster M; Mazzaferri E; Weston AR
Eur J Endocrinol; 2006 Sep; 155(3):405-14. PubMed ID: 16914594
[TBL] [Abstract][Full Text] [Related]
32. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases.
Taïeb D; Jacob T; Zotian E; Mundler O
Thyroid; 2004 Jun; 14(6):465-7. PubMed ID: 15242576
[TBL] [Abstract][Full Text] [Related]
33. 131I therapy using rhTSH stimulation and dosimetry in metastatic malignant struma ovarii.
Yan J; Lewis DH; Benoit MF; Eary JF; Mankoff DA
Clin Nucl Med; 2014 Jan; 39(1):102-5. PubMed ID: 24152665
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis.
Risse JH; Grünwald F; Bender H; Schüller H; Van Roost D; Biersack HJ
Thyroid; 1999 Dec; 9(12):1253-6. PubMed ID: 10646667
[TBL] [Abstract][Full Text] [Related]
35. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer.
Zanotti-Fregonara P; Hindié E
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2264-6. PubMed ID: 20821206
[No Abstract] [Full Text] [Related]
36. Clinical review 156: Recombinant human thyrotropin and thyroid cancer management.
Robbins RJ; Robbins AK
J Clin Endocrinol Metab; 2003 May; 88(5):1933-8. PubMed ID: 12727936
[No Abstract] [Full Text] [Related]
37. Expanding indications for recombinant human TSH in thyroid cancer.
Haugen BR; Cooper DS; Emerson CH; Luster M; Maciel RM; Biscolla RP; Mazzaferri EL; Medeiros-Neto G; Reiners C; Robbins RJ; Robinson BG; Schlumberger M; Yamashita S; Pacini F
Thyroid; 2008 Jul; 18(7):687-94. PubMed ID: 18630995
[No Abstract] [Full Text] [Related]
38. [A decade of recombinant human thyrotropin].
Rodríguez-Merchán B; Mesa J
Med Clin (Barc); 2009 Apr; 132(14):560-4. PubMed ID: 19393392
[No Abstract] [Full Text] [Related]
39. What role for recombinant human TSH in the treatment of metastatic thyroid cancer?
Zanotti-Fregonara P; Hindié E; Toubert ME; Rubello D
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):883-5. PubMed ID: 19153732
[No Abstract] [Full Text] [Related]
40. Recombinant human thyrotropin.
Hershman JM
Thyroid; 1999 May; 9(5):419-20. PubMed ID: 10365670
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
